Index

Note: Page numbers with italicized f's and t's refer to figures and tables.

A Diabetes Outcome Progression Trial (ADOPT), 111
Aberdeen Diabetic Clinic, 108
acarbose, 7
acromegaly, 24
Action to Control Cardiovascular Risks in Diabetes (ACCORD), 44, 100, 150
acute coronary syndromes, 147–8
adenosine 5′-monophosphate protein kinase (AMPK), 79–80
adolescents with diabetes
continuous glucose monitoring in, 51
cystic fibrosis-related diabetes, 26
diet, 61
environmental factors, 15–17
type 1 diabetes, 11
ADOPT trial, 7
ADVANCE study, 100
Air Force/Texas Coronary Atherosclerosis Prevention Study, 38
alanine amino transferase, 86
albiglutide, 92
ambulatory glucose profile (AGP), 51–2, 52
amylin, 93
Angioplasty Compared to Medical Therapy (ACME) trial, 148
angiotensin converting enzyme (ACE) inhibitor, 150
antiCD3 monoclonal antibody, 19
anti-interleukin-1, 20
antipsychotic drugs, 30–31, 65
apolipoproteins, 37
ARBITER study, 124
ARCHIMEDES, 36–7
aripriazole, 65
atherosclerosis, 5, 116, 123
Atherosclerosis Risk in Communities Study (ARIC), 5
atorvastatin, 118f. 119
AusDiab study, 5
autoantibodies, 12
autoimmune diabetes, 22
average glucose, 97
BABYDIET study, 16–17
Baltimore Longitudinal Study of Aging, 6
BARI 2D trial, 149–50
bariatric surgery, 127–32. See also obesity; revascularization
gastric banding, 130–31
gastric bypass, 130–31
incretin, effect of, 128
side effects, 110f
for type 2 diabetes, 128–9
weight loss and, 113, 128
basal energy expenditure, 141f
beta casein, 13–14
beta lactoglobulin, 14
beta-cell function, 6, 15f, 65–6, 75
bezafibrate, 123–4
Bezafibrate Infarction Prevention (BIP), 123–4
biguanides, 79–83, 111. See also insulin sensitizers
efficacy of combination therapy, 81–2
mechanism of action, 79–81
pharmacokinetics, 81
polycystic ovary syndrome, 82–3
thiazolidinediones, 83–8
bilio-pancreatic diversion (BPD), 130–31
blood glucose, 135–6
capillary, 4, 80
carbohydrate counting, 62
control. See glucose control
estimate of average glucose, 97f
fasting, 129
HbA1c and, 97
hyperglycemia, 135–6
hypoglycemia, 60
metformin and, 83
pharmacotherapy, 65
self-monitoring, 43–54
testing, 139–40
thiazolidinediones and, 85
body mass index (BMI), 57f, 107, 131–2.
See also obesity
body weight, 73
bone disease, 73
bovine beta casein, 13–14
buformin, 79
C282Y mutation, 23–5
calcineurin inhibitors, 29, 65
calcitriol, 19
calcium, 59–60

Clinical Dilemmas in Diabetes, First Edition. Edited by Adrian Vella and Robert A. Rizza
© 2011 Blackwell Publishing Ltd. Published 2011 by Blackwell Publishing Ltd.
Index

caloric restriction, 67
calories, 57–8
cancer, 73–4
carbohydrate counting, 62

carbohydrates, 58

cardiac risk equivalent, 34
cardiorespiratory fitness (CRF), 68
cardiovascular disease, 34–9.
See also coronary heart disease (CHD);
obesity
glucose metabolism and, 121
highly sensitive C-reactive protein, 38
hyperglycemia and, 35–6
insulin sensitizers and, 74–5
meglitinides and, 74
metabolic syndrome, 36–7
metformin and, 74–5
nontraditional risk factors, 38
risk factors, 36–8
risk stratification, 36–7
sulfonylureas and, 74
thiazolidinediones and, 75
carotid intima-media thickness (CIMT), 87
casein, 13–14
children with diabetes
continuous glucose monitoring in, 51
cystic fibrosis-related diabetes, 26
diet, 17, 61
environmental factors, 13
identification, 15–17
type 1 diabetes, 11–12
vitamin D deficiency in, 14
weight maintenance in, 61
cholesterol, 38, 58r, 59, 73, 86–7, 116, 117f
Cholesterol and Recurrent Events (CARE) trial, 118
cirrhosis, 23, 25, 86
clozapine, 30, 65
cod liver oil, 14
Collaborative Atorvastatin Diabetes Study (CARDS), 119
congenital rubella, 13
congestive heart failure (CHF), 87–8
continuous glucose monitoring (GCM), 50–54. See also self-monitoring of blood glucose (SMBG)
closed-loop system, 51
commercial devices, 52f
estimate of average glucose, 97
HbA1c measurement, 97
outputs, 52–3f
sensor burnout, 51
continuous subcutaneous insulin infusion (CSII), 49
coronary artery bypass grafting (CABG), 145–51. See also percutaneous coronary intervention (PCI)
in acute coronary syndromes, 147–8
class I indications for, 146f
clinical trials, 148–50
vs. percutaneous coronary intervention, 147
rationale for, 147
risk factor modification, 150–51
Coronary Artery Calcium Scoring (CAC), 38–9
coronary artery disease (CAD), 59, 74, 87, 119–20, 149
coronary heart disease (CHD), 145. See also cardiovascular disease dyslipidemia and, 118–20
hypertriglyceridemia and, 120–23
metabolic syndrome and, 117
nonfasting triglyceride level and, 123
prevention of, 119
risk for, 4
type 2 diabetes and, 116
weight fluctuations and, 108
coronary revascularization, 145–51
for myocardial infarction, 148–50
for prolonging life, 148–50
recommendations for, 145–6
risk factor modification, 150–51
for symptom control, 147–8
corticosteroids, 65
COUrage trial, 35, 148
cow’s milk, 13–14
Coxsackievirus B serotypes, 13
C-reactive protein (CRP), 38
Cushing’s syndrome, 24f, 28–9.
See also secondary diabetes
cyclosporin, 19, 29, 66, 119–20
cystic fibrosis transmembrane regulator (CFTR), 26
cystic fibrosis-related diabetes (CFRD), 25–8. See also secondary diabetes
clinical features, 27f
cow’s milk and, 13–14
defined, 22
early diagnosis of, 11–20
incidence of, 11
pathogenesis of, 12–13
prediction of, 14
cytomegalovirus, 13
cytotoxic T lymphocyte antigen 4 (CTLA-4), 12
Da Qing IGT and Diabetes Study, 6
DECODE study, 5, 35
Detection of Ischemia in Asymptomatic Diabetics (DIAD), 35
Diabetes Atherosclerosis Intervention Study (DAIS), 124
Diabetes Control and Complications Trial (DCCT), 44, 97
Diabetes Glycaemic Education and Monitoring (DiGem) study, 45
diabetes mellitus, 22
body mass index and, 107
cardiovascular disease and, 34–9
continuous glucose monitoring, 50–54
coronary revascularization in, 145–51
flatbush diabetes, 30
genetic forms, 32
HbA1c and, 96–102
incretin-based therapy, 91–4
lifestyle changes vs. pharmacotherapy, 64–9
medical nutrition therapy, 56–63
post-transplant, 29–30
secondary, 22–32
antipsychotic drugs and, 30–31
cystic fibrosis-related diabetes (CFRD), 25–8
definition of, 22
hemochromatosis, 23–5
HIV infection, 31
hormone excess, 24f, 28–9
pancreatic disease, 24f
pancreatic-cancer-associated diabetes, 28
post-transplant diabetes mellitus, 29–30
self-monitoring of blood glucose, 43–50
type 1 diabetes, 11–20, 119–20
beta-cell mass, preserving, 15f
clinical features, 27f
cow’s milk and, 13–14
defined, 22
early diagnosis of, 11–20
incidence of, 11
pathogenesis of, 12–13
prediction of, 14
prevalence of, 11
prevention of, 14–20, 15f, 15t
self-monitoring of blood glucose, 44–5
vitamin D deficiency and, 14
type 2 diabetes, 22
bariatric surgery for, 127–32
clinical features, 27
dyslipidemia in, 116–18
insulin-requiring, 44–5
non-insulin-requiring, 45–8
obesity and, 107–14
self-monitoring of blood glucose, 44–8
Diabetes Prediction and Prevention Project (DIPP), 17
Diabetes Prediction and Prevention Trial-Type 1 (DPT-1), 17–18
Diabetes Prevention Program, 7, 67
diabetic ketoacidosis, 30
DIABFIN study, 16
DiaPep277, 19–20
diet, 56–63
alcohol, 60
calories, 57–8
carbohydrate counting, 62
carbohydrates, 58
for children/adolescents with diabetes, 61
fiber, 58t
glycemic index, 63
hypoglycemia and, 60
implementation, 61–2
vs. intensive glucose control, 112
lifestyle changes and, 68t
macronutrients, 59
micronutrients, 59–60
obesity and, 108–11
pregnancy and, 60–61
proteins, 58–9
recommendations, 57t
sweeteners, 60
weight management and, 61
dipeptidyl peptidase-4 (DPP-4), 47, 92, 110t, 112
DR15–DQ6 HLA haplotype, 12
DR3–DQ2 HLA haplotype, 12
DR4–DQ8 HLA haplotype, 12
DREAM trial, 7
dyslipidemia, 116–20. See also hypertriglyceridemia
insulin resistance and, 117f
secondary causes of, 117
treatment of, 118–20
in type 2 diabetes, 116–18
Enterovirus, 13
EPIC-Norfolk study, 36
Epidemiology of Diabetes Interventions and Complications (EDIC), 44
estimate of average glucose (eAG), 97
European Nicotinamide Diabetes Intervention Trial (ENDIT), 17
exenatide, 92–3, 109f
exercise, 34, 66–8
fats/fatty acids, 58
monounsaturated, 58, 59.
nonesterified free, 117
omega-3, 59
polyunsaturated, 58
saturated, 58
trans, 58t
fenofibrate, 123
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD), 123
fiber, 58. See also medical nutrition therapy (MNT)
fibrates, 123–4
Finnish Diabetes Prevention Study, 6
flatbush diabetes, 30
folic acid, 59–60
fractures, risk of, 73
Framingham Heart Study Cohort, 108
free fatty acids (FFAs), 117, 135
French lilac, 79
FRISC II trial, 148
fructose, 60
GAD65, 19
Galega officinalis, 79
gastric banding, 110t,
130–31
gastric bypass surgery, 67, 110t, 130–31
gemfibrozil, 118f
gestational diabetes mellitus, 48
glargine, 24, 31, 74, 92
Global Registry of Acute Coronary Events, 148
glucagon-like peptide (GLP-1), 47, 92–4, 112, 128
hypoglycemia and, 99
hyperglycemia and, 100–101
hyperglycemia and, 99
insulin sensitizers, 72–3
international goals, 100f
macrovascular effects of, 100
meätinides, 72–3
meta-analysis, 99
metformin, 72–3
microvascular effects of, 100
observational studies, 98–9
physiologic studies, 98
primary outcome, 99t
randomized controlled trials, 99
risks, 99–101
secretagogues, 72–3
sensitizers, insulin, 72–3
sulfonylureas, 72–3
thiazolidinediones, 72–3
value of, 101
weight gain and, 99–100
glucose hypothesis, 96
glucose-dependent insulino-tropic polypeptide (GIP), 92, 128
glucotoxicity, 66
GLUT-1 transporters, 80
GLUT-4 transporters, 80
glyburide, 75
glycated hemoglobin. See HbA1c (glycated hemoglobin)
glycemic index, 63
glycosuria, 97
goat's rue, 79
Harris Benedict equation (HBE), 57–8
HbA1c (glycated hemoglobin), 96–102.
See also self-monitoring of blood glucose (SMBG)
average glucose and, 97
cardiovascular disease and, 36
glucose control, 98–102
glycemic exposure, 98
lifestyle modification and, 67
HbA1c (glycated hemoglobin) (cont.) measurement of, 98 self-monitoring of blood glucose, 45–6 standardization, 97 weight loss and, 112 Heart Protection Study (HPS), 119 heat shock protein, 19–20 hemochromatosis, 23–5. See also secondary diabetes natural history, 23–5 screening, 24t, 25 hepatitis C, 29 hepatocyte nuclear factor 1-alpha (HNF1A), 32 hereditary hemochromatosis, 23–5 natural history, 23–5 screening, 24t, 25 high-density lipoprotein (HDL) cholesterol, 59, 73, 86–7, 116, 117 highly active antiretroviral therapy (HAART), 31, 86–7 highly sensitive C-reactive protein (hsCRP), 38 Himsworth, Harold Percival, 79 HIV infection, 31 hormone excess, 28–9. See also secondary diabetes human leukocyte antigen (HLA), 12 hyperglycemia, 134–42. See also hypoglycemia adverse effects, 134–5 APACHE scores/mortality data, 138t development of, 6 glycemic treatment goals for, 100–101 intervention studies, 135–8 pharmacotherapy and, 65 prevalence rate, 134 risk of cardiovascular disease and, 35–6 hyperlipidemia, 107 hypertension congestive heart failure and, 87 obesity and, 1–7, 107, 117 prediabetes and, 4 revascularization and, 150 secondary diabetes and, 23 sodium restriction, 60 hypertriglyceridemia, 116–17 alcohol intake and, 60 coronary heart disease risk and, 120–23 metabolic syndrome and, 124 treatment of, 123–5 hypoglycemia, 60. See also hyperglycemia in critical illness/postoperative period, 138–9 glucose control and, 99 glucose testing, 139–40 risk of, 73 immunosuppressants, 65–6 impaired fasting glucose (IFG), 3–4, 6, 36 impaired glucose tolerance (IGT), 3–4, 36 incretin, 91–4, 112, 128 Indian Diabetes Prevention Programme, 6 insulin glargine, 24, 31, 74, 92 insulin insensitivity, 79 insulin resistance, 117f insulin sensitizers, 71–6. See also secretagogues beta-cell preservation, 75 biguanides, 79–83 body weight, effect on, 73 bone disease, risk of, 73 cancer risk and, 73–4 cardiovascular disease and, 74–5 case study, 80 cost-effectiveness of, 76 durability, 75 end-points, 72r glucose control, 72–3 hypoglycemia, risk of, 73 insulin therapy and, 79–89 lipid effects, 73 risks, 75–6 vs. secretagogues, 71–6 insulin therapy, 27 anti-CD3 and, 19 caloric restriction and, 67 carbohydrate counting and, 62 cardiac surgery and, 150 in gestational diabetes mellitus, 48 for hyperglycemia, 135–6 for hypoglycemia, 139 incretin and, 93 insulin sensitizers and, 81–9 self-monitoring of blood glucose and, 44–5 insulin-dependent diabetes, 22 INTERHEART study, 37–8 internal thoracic artery (ITA), 149 islet cell antibodies (ICA), 12 JUPITER trial, 38 ketoacidosis, 66 ketosis-prone type 2 diabetes, 30 Kineret, 20 Kumamoto study, 97 lactic acidosis, 83 legacy effect, 44 lifestyle changes, 64–9 lipodystrophies, 87 liraglutide, 92, 112 liver cirrhosis, 23, 25, 86 Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study, 118–19 Look AHEAD (Action for Health in Diabetes), 68 low-density lipoprotein (LDL) cholesterol, 38, 73, 86–7, 116 lymphoid phosphatase (LYP), 12 M2 muscarinic receptors, 65 macronutrients, 58–9. See also medical nutrition therapy (MNT) carbohydrates, 58 fats, 59 fiber, 58r proteins, 58–9 macrovascular disease, 3–4 maturity onset diabetes of the young syndrome (MODY), 32 measles, 13 medical nutrition therapy (MNT), 56–63 alcohol, 60 calories, 57–8 carbohydrate counting, 62 carbohydrates, 58 for children/adolescents with diabetes, 61 fats, 59 fiber, 58r glycemic index, 63 goals, 56 hypoglycemia and, 60 implementation, 61–2 macronutrients, 59 micronutrients, 59–60
pregnancy and, 60–61
proteins, 58–8
sweeteners, 60
meglitinides. See also insulin sensitizers
body weight, effect on, 73
cardiovascular disease and, 74
cost effectiveness of, 76
end-points, 72
end-points, 72
end-points, 72
end-points, 72
end-points, 72
deficiency, 75
insulin sensitizers
adverse effects, 83
gastrointestinal, 48
lactic acidosis, 83
beta-cell preservation, 75
cancer risk and, 74–5
contraindications, 83
direct/indirect effects, 80

t
durability, 75
efficacy of combination therapy, 81–2
end-points, 72
fatty acids and, 82
fatty acids and, 82
fatty acids and, 82
fatty acids and, 82
fatty acids and, 82
fatty acids and, 82
fatty acids and, 82
fatty acids and, 82
indicators, 82–3
lifestyle intervention and, 64–5
lipid effects, 73
mechanism of action, 79–81, 81
pharmacokinetics, 81
in prediabetes management, 6
risks, 75
self-monitoring of blood glucose and,
side effects, 109–10
weight loss and, 111–12
micronutrients, 59–60. See also medical
nutrition therapy (MNT)
microvascular disease, 4
milk albumin, 13–14
monounsaturated fatty acids (MUFAs),
58, 59
mumps, 13
myocardial infarction, 123–4, 148–50
nateglinide, 72
National Glycohemoglobin Standardization Program (NGSP), 97
National Screening Committee (NSC),
23–5
NAVIGATOR trial, 7
nephropathy, 4–5
new-onset diabetes mellitus after
transplantation (NODAT), 29
nicotinamide, 19
nonalcoholic fatty liver disease (NAFLD),
86
non-autoimmune diabetes, 22
noninsulin-dependent diabetes, 22
non-insulin-dependent diabetes, 22
non-insulin-treated type 2 diabetes, 45–8
non-ST-segment elevation myocardial
infarction (NSTEMI), 147–8
normoglycemia, 6
nutrition support, 140–42
obesity, 107–14
bariatric surgery for, 113, 127–32
body mass index and, 57,
107

t
exercise for, 112–13
hypertension and, 107
weight loss, 108
olanzapine, 30, 65
omega-3 fatty acids, 3
oral glucose, 3–4, 73, 128. See also blood
glucose
oral glucose tolerance test (OGTT), 5–6,
18, 24f, 26–7, 30
oralistat, 110f, 113
overweight, 57t, 58, 67, 74, 107–8, 111.
See also obesity
pancreatic cancer, 24
pancreatic-cancer-associated diabetes, 28
percutaneous coronary intervention
(PCI), 147–50
in acute coronary syndromes, 147–8
for asymptomatic patients with
diabetes, 35
clinical trials, 148–50
vs. coronary artery bypass grafting, 147
recommendations for, 146
peroxisome-proliferator-activated
receptors (PPARs), 83–5
phaeochromocytoma, 24
pharmacotherapy, 64–9
phenformin, 79
phaeochromocytoma, 28
Pima Indians, 4–5
pioglitazone, 73
polycystic ovary syndrome, 82–3, 86
polydipsia, 66
polyunsaturated fatty acids (PUFAs), 58t,
59
polyuria, 66
postprandial glucose, 49–50
postprandial self-monitoring of blood
glucose, 48–50
See also secondary diabetes
clinical features, 29–30
incidence of, 29
risk factors, 29
screening, 30
pramlintide, 93
pravastatin, 118
prediabetes, 3–7
atherosclerosis and, 5
definition of, 3
management of, 6–7
microvascular effects of, 4
oral glucose tolerance test, 5–6
prevalence rate, 3
pregnancy
diet and, 60–61
gestational diabetes mellitus, 48
self-monitoring of blood glucose in, 48
PREVEFIN study, 16
proteins. See also medical nutrition
therapy (MNT)
PTPN22 gene, 12
Rahbar, Samuel, 96
Randomized Intervention Treatment of
Angina (RITA) trial, 148
Reaven, Gerald, 79
repaglinide, 72
resting energy expenditure, 57–8
retinopathy, 4–5
retroviruses, 13
revascularization, 145–51. See also
coronary artery bypass grafting
(CABG)
in preventing subsequent myocardial
infarction, 148–50
for prolonging life, 148–50
recommendations for, 145–6
risk factor modification, 150–51
for symptom control, 147–8
Index

risperidone, 65
RNA viruses, 13
rosiglitazone, 7, 73, 75, 111
Roux-en-Y gastric bypass (RYGB), 67, 130–31
San Antonio Heart Study, 5
saturated fatty acids, 58, 59
saxagliptin, 92
schizophrenia, 65
screening
  cardiovascular disease, 34–9
  cystic fibrosis-related diabetes (CFRD), 27–8
  hematochromatosis, 25
  post-transplant diabetes mellitus, 30
  prediabetes, 34–9
  secondary diabetes, 22–32
  antipsychotic drugs and, 30–31
  cystic fibrosis-related diabetes (CFRD), 25–8
  definition of, 22
  hematochromatosis, 23–5
  HIV infection, 31
  hormone excess, 24
  pancreatic disease, 24
  pancreatic-cancer-associated diabetes, 28
  post-transplant diabetes mellitus, 29–30
secretagogues, 71–6. See also insulin sensitizers
beta-cell preservation, 75
body weight, effect on, 73
bone disease, risk of, 73
cancer risk and, 73–4
cardiovascular disease and, 74–5
  cost-effectiveness of, 76
durability, 75
diabetes, risk of, 72r
glucose control, 72–3
hypoglycemia, risk of, 73
lipid effects, 73
  risks, 75–6
side effects, 109r
self-monitoring of blood glucose
  (SMBG), 43–50. See also continuous glucose monitoring (CGM)
legacy effect/metabolic memory, 44

in non-insulin-treated type 2 diabetes, 45–8
postprandial, 48–50
in type 1 diabetes, 44–5
in type 2 diabetes, 44–5
sensitizers, insulin, 71–6
beta-cell preservation, 75
body weight, effect on, 73
disease, risk of, 73
cancer risk and, 73–4
cardiovascular disease and, 74–5
cost-effectiveness of, 76
durability, 75
diabetes, risk of, 72r
glucose control, 72–3
hypoglycemia, risk of, 73
lipid effects, 73
  risks, 75–6
sibutramine, 110, 112
Sibutramine Cardiovascular Outcome Trial (SCOUT), 112
simvastatin, 118
sitagliptin, 92, 112
sodium, 60
somatostatinoma, 28
South Asians, 6
ST elevation myocardial infarction (STEMI), 147–8
statins, 119
Stop-NIDDM trial, 50
sucrose, 58, 60
sugar alcohols, 60
sulfonylureas, 71. See also insulin sensitizers
  body weight, effect on, 73, 111
cardiovascular disease and, 74
durability, 75
diabetes, risk of, 73
hypoglycemia, risk of, 73
  vs. insulin sensitizers, 71–6
lipid effects, 73
  risks, 75–6
side effects, 109r
tacrolimus, 29, 66
taspodiglutide, 92
thiazolidinediones, 83–8, 91–2. See also insulin sensitizers
  adverse effects, 88
  body weight, effect on, 73
  bone disease, risk of, 73
cancer risk and, 74
cardiovascular disease and, 75
clinical trials, 86
contraindications, 87–8
cost effectiveness of, 76
durability, 75
effects of, 85–6
diabetes, risk of, 72r
glucose control, 72–3
glycemic control and, 47
indications, 86–7
carotid intima-media thickness, 87
lipid lowering, 86–7
lipodystrophies, 87
nonalcoholic fatty liver disease, 86
polycystic ovary syndrome, 86
  lipid effects, 73
mechanism of action, 84–5
peroxisome-proliferator-activated receptors, 83–4
pharmacokinetics, 85
  risks, 75–6
side effects, 109r
thyroxine, 140
transt-fatty acids, 58r
Treating to New Targets (TNT) study, 119
TRIGR trial, 16
troglitazone, 6–7, 89
type 1 diabetes mellitus, 11–20
  beta-cell mass, preserving, 15f
  in children/adolescents, 11
clinical features, 27r
cow’s milk and, 13–14
defined, 22
early diagnosis of, 11–20
incidence of, 11
pathogenesis of, 12–13
prediction of, 14
prevalence of, 11
prevention of, 14–20, 15f
  primary, 15–17
  secondary, 17–18
  tertiary, 19–20
self-monitoring of blood glucose, 44–5
  statin therapy for, 119
vitamin D deficiency and, 14
type 2 diabetes mellitus
  bariatric surgery for, 127–32
Index

clinical features, 27t

dyslipidemia in, 116–18

insulin-requiring, 44–5

non-insulin-requiring, 45–8

obesity and, 107–14

self-monitoring of blood glucose, 44–8

United Kingdom Prospective Diabetes Study (UKPDS), 44, 97, 100

University Group Diabetes Program (UGDP), 74

unstable angina, 148

US Preventive Services Taskforce, 23

vertical sleeve gastrectomy, 128

very low density lipoprotein (VLDL), 116, 117t

Veterans Administration Diabetes Trial (VADT), 100

vildagliptin, 112

visual impairment, 4

vitamin D, 19

vitamin D deficiency, 14

weight gain

antipsychotics and, 65

glucose control and, 99–100

weight loss

bariatric surgery, 128, 131–2

lifestyle changes and, 68t

obesity and, 108

pharmacotherapy and, 66

weight management, 61. See also obesity

Wolfram syndrome, 32